Get the Stockscreener App
4.95
2.48%
0.12
Cvrx Inc stock is traded at $4.95, with a volume of 293.20K.
It is up +2.48% in the last 24 hours and down -16.67% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$4.83
Open:
$4.92
24h Volume:
293.20K
Relative Volume:
0.98
Market Cap:
$131.35M
Revenue:
$59.07M
Net Income/Loss:
$-52.66M
P/E Ratio:
-2.4627
EPS:
-2.01
Net Cash Flow:
$-40.16M
1W Performance:
+1.23%
1M Performance:
-16.67%
6M Performance:
-37.50%
1Y Performance:
-15.09%
1-Day Range:
$4.85
$5.005
1-Week Range:
$4.77
$5.24
52-Week Range:
$4.3701
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
4.95 | 131.35M | 59.07M | -52.66M | -40.16M | -2.01 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRx Inc (CVRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CVRx Inc (CVRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CVRx Inc (CVRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CVRx Inc (CVRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CVRx Inc (CVRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVRx Inc (CVRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CVRx Inc (CVRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
CVRx Inc (CVRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
CVRX: CFO transition, expanded clinical trials, and improved reimbursement drive growth and adoption - TradingView
CVRX: CFO transition, strong Q1 growth, and expanded reimbursement drive U.S. market momentum - TradingView
CVRx CFO Jared Oasheim to step down after decade with company By Investing.com - Investing.com Australia
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating - Moomoo
CVRx CFO Jared Oasheim to step down - MSN
CVRx CFO Jared Oasheim to step down after decade with company - Investing.com Australia
CVRx CFO Jared Oasheim to Resign, Will Stay Through Transition and Serve as Consultant - TradingView
Jared Oasheim to Resign as Chief Financial Officer of CVRx, Inc - marketscreener.com
[8-K] CVRx, Inc. Reports Material Event - Stock Titan
CVRx Announces Chief Financial Officer Transition - The Globe and Mail
CVRx Chief Financial Officer Jared Oasheim Leaving - Moomoo
Medical device firm CVRx plans CFO change, keeps him through Feb. 2027 - Stock Titan
CVRx stock up on Humana's Medicare coverage for Barostim therapy - MSN
CVRx, Inc. (CVRX) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
CVRx (NASDAQ: CVRX) director Nielsen awarded shares and 11,182-share option - Stock Titan
CVRx, Inc. (CVRX) director receives new share and option grants - Stock Titan
[Form 4] CVRx, Inc. Insider Trading Activity - Stock Titan
CVRx (CVRX) director granted 8,720 shares and options for 11,182 - Stock Titan
CVRx (CVRX) director receives new share and stock option awards - Stock Titan
Martha Shadan of CVRx, Inc. (CVRX) receives stock and option grants - Stock Titan
CVRx, Inc. (CVRX) director granted shares and stock options - Stock Titan
[Form 3] CVRx, Inc. Initial Statement of Beneficial Ownership - Stock Titan
William Blair Maintains CVRx Inc(CVRX.US) With Buy Rating - 富途牛牛
CVRx (CVRX) investors re-elect directors and ratify Grant Thornton as auditor - Stock Titan
CVRx, Inc. Elects Michael Dale as Director - marketscreener.com
Why (CVRX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
CVRX: Barostim drives heart failure innovation with strong clinical results and expanding market access - TradingView
CVRX: Barostim's clinical success and new Humana coverage drive expanded heart failure market access - TradingView
CVRx to present at Goldman Sachs Healthcare Con... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
CVRx Inc. (CVRX) Slips 1.04% as Stock Hovers Near Key Support ZoneMean Reversion Trade - thelegaladvocate.com
Understanding Momentum Shifts in (CVRX) - Stock Traders Daily
CVRx, Inc.Common Stock (NQ: CVRX - The Chronicle-Journal
CVRX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Operational DisciplineFinal Results - lwvtexas.org
Clinical research teams accelerate progress in treatment options, CVRx asserts - Traders Union
CVRx to Present at the William Blair 46th Annual Growth Stock Conference - 富途牛牛
What Humana (HUM)'s Expanded Barostim Coverage Means For Shareholders - simplywall.st
CVRx to present at William Blair Growth Stock Conference on June 2, 2026 - Pluang
CVRx marks 25th Barostim implant milestone at UNC Medical Center Chapel Hill - Traders Union
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy - Yahoo Finance
CVRx rebounds as Humana issues Medicare policy for Barostim - MSN
CVRx Inc stock (US12674F1003): Medtronic takeover bid puts heart-device specialist in the spotlight - AD HOC NEWS
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):